Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal down12.960 -0.300 (-2.262%)

15/10/2021 13:53

CMS (00867) gets new drug application accepted

[ET Net News Agency, 15 October 2021] China Medical System Holdings Limited (00867)
said new drug application of the group's innovative drug Tildrakizumab solution for
injection has been accepted by the National Medical Products Administration of the
People's Republic of China.
The product is indicated for the treatment of adults with moderate-to-severe plaque
psoriasis who are candidates for systemic therapy or phototherapy, and has been approved
for marketing in the U.S., Australia, European Union, Switzerland, Japan and Canada. (RC)

Remark: Real time quote last updated: 29/11/2021 11:56
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2021 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.